In Response to “Five-Year Patient-reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?” Pierre Blanchard, Chiara Sighinolfi, Mario Terlizzi, et al. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.07.023
In Response to “Five-Year Patient-reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?” Pierre Blanchard, Chiara Sighinolfi, Mario Terlizzi, et al. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.07.023. // European Urology. – URL: https://www.sciencedirect.com/science/article/pii/S0302283826024413?dgcid=rss_sd_all
In Response to “Five-Year Patient-reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?” Pierre Blanchard, Chiara Sighinolfi, Mario Terlizzi, et al. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.07.023. European Urology. https://www.sciencedirect.com/science/article/pii/S0302283826024413?dgcid=rss_sd_all
“In Response to “Five-Year Patient-reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?” Pierre Blanchard, Chiara Sighinolfi, Mario Terlizzi, et al. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.07.023.” European Urology.
@article{article93849,
title = {In Response to “Five-Year Patient-reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?” Pierre Blanchard, Chiara Sighinolfi, Mario Terlizzi, et al. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.07.023},
journal = {European Urology},
url = {https://www.sciencedirect.com/science/article/pii/S0302283826024413?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...